Al­ler­gan caps a bad day with news the FDA has kicked back a sup­ple­men­tal ap­pli­ca­tion for cariprazine

Al­ler­gan $AGN is not hav­ing a good day to­day.

Af­ter post­ing some mixed, weak ex­tend­ed year-two da­ta on its NASH drug, the com­pa­ny end­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.